Article
Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinoma
20 May 2025
Abstract excerpt
PURPOSE: To explore the failure patterns, outcomes, and treatment response of differentiated non-keratinizing nasopharyngeal carcinoma (DNKC) and to further investigate the role of plasma Epstein-Barr virus (EBV)-DNA in follow-up monitoring, prognostic prediction, and assessment of treatment efficacy in DNKC. METHODS: We retrospectively collected data from patients diagnosed with DNKC from January 2015 to...
Topics
Join the communities discussing this publication.
